Imunon Inc 2024年度报告

FORM 10-K (Mark One) For the fiscal year ended December 31, 2024. or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _______ to _______ COMMISSION FILE NO.:001-15911 IMUNON, INC.(Exact Name of Registrant as Specified in Its Charter) Registrant’s telephone number, including area code:(609) 896-9100 Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, Par Value $0.01 Per ShareIMNNThe Nasdaq Stock Market LLC Securities registered pursuant to section 12(g) of the Act:None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was requiredto file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter periodthat the Registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the Registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large Accelerated FilerNon-accelerated Filer If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct.☐ Indicate by check mark whether the Registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b))by the registered public accounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to§240.10D-1(b).☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of1934). Yes☐No☒ The aggregate market value of the common stock held by non-affiliates of the Registrant was approximately $10.8 million asof June 28, 2024 (the last business day of the Registrant’s most recently completed second fiscal quarter) based on the closingsale price of $1.16. for the Registrant’s common stock on that date as reported by The Nasdaq Capital Market (“NASDAQ”).For purposes of this calculation, shares of common stock held by directors, officers and stockholders who own greater than10% of the Registrant’s outstanding stock at June 30, 2024, were excluded. This determination of executive officers anddirectors as affiliates is not necessarily a conclusive determination for any other purpose. As of February 21, 2025, 14,620,732 shares of the Registrant’s common stock were issued and outstanding. None. IMUNON, INC.FORM 10-KTABLE OF CONTENTS PART I ITEM 1.BUSINESS.................................................................................................................................................1FORWARD-LOOKING STATEMENTS..................................................................................................1OVERVIEW ..............................................................................................................................................2THERAPLAS MODALITY: IMNN-001 DEVELOPMENT PROGRAM................................................2Ovarian Cancer Overview ..........................................................................................................2IMNN-001 Immunotherapy .......................................................................................................3OVATION I Study .....................................................................................................................